In Brief: FDA testing, FDA inspection creep, Q11 ‘clarified,’ enforcement dashboard, data integrity, more
This article was originally published in The Gold Sheet
FDA posts testing results; regulatory creep knocks at door; ICH Q11 ‘clarified’ for Europe; FDA’s new enforcement dashboard; data integrity insights; FDA’s Arista challenges India; FDA’s new quality platform.
You may also be interested in...
FDA tweaks final guidance on what constitutes interference with FDA inspections to include examples of ‘reasonable’ explanations for sponsor delays; industry had requested many other changes.
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.
Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.